Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a Study of SLV213 in Ambulatory COVID-19 Patients
NCT04843787Phase 2Unknown
- Start
- Nov 2023
- Primary completion
- Jun 2024
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
01
Overview
A Phase 2 trial of SLV213 in coronavirus disease 2019 (COVID-19). Status: unknown.
02
Drugs
SLV213
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04843787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04843787.